ABN Amro Investment Solutions Sells 8,219 Shares of Amgen Inc. $AMGN

ABN Amro Investment Solutions lessened its position in Amgen Inc. (NASDAQ:AMGN) by 12.5% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 57,571 shares of the medical research company’s stock after selling 8,219 shares during the period. ABN Amro Investment Solutions’ holdings in Amgen were worth $16,247,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the company. Sequoia Financial Advisors LLC lifted its holdings in shares of Amgen by 2.3% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 160,646 shares of the medical research company’s stock valued at $45,334,000 after purchasing an additional 3,619 shares in the last quarter. Atlantic Union Bankshares Corp raised its holdings in Amgen by 165.0% during the 2nd quarter. Atlantic Union Bankshares Corp now owns 10,643 shares of the medical research company’s stock worth $2,972,000 after buying an additional 6,627 shares during the period. Davis Capital Management bought a new position in Amgen in the third quarter valued at approximately $1,841,000. D.A. Davidson & CO. lifted its stake in Amgen by 2.6% in the third quarter. D.A. Davidson & CO. now owns 243,054 shares of the medical research company’s stock valued at $68,590,000 after buying an additional 6,222 shares in the last quarter. Finally, Global Wealth Management Investment Advisory Inc. boosted its holdings in shares of Amgen by 56.2% in the third quarter. Global Wealth Management Investment Advisory Inc. now owns 13,056 shares of the medical research company’s stock valued at $3,684,000 after buying an additional 4,699 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 3,139 shares of the firm’s stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $337.26, for a total value of $1,058,659.14. Following the completion of the sale, the senior vice president directly owned 7,225 shares in the company, valued at approximately $2,436,703.50. This trade represents a 30.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.76% of the company’s stock.

Wall Street Analysts Forecast Growth

AMGN has been the topic of a number of research analyst reports. TD Cowen restated a “buy” rating on shares of Amgen in a report on Wednesday, February 4th. Wall Street Zen downgraded Amgen from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 7th. Guggenheim boosted their price target on Amgen from $305.00 to $347.00 and gave the company a “neutral” rating in a report on Friday, February 6th. Sanford C. Bernstein downgraded Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price objective for the company. in a report on Tuesday, January 20th. Finally, UBS Group lifted their target price on Amgen from $380.00 to $390.00 and gave the company a “buy” rating in a research report on Monday, January 26th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $354.04.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: European Commission approval for Uplinza (amifampridine) for generalized myasthenia gravis expands Amgen’s labelled indications in Europe and supports incremental near-term revenue potential for the product. Amgen wins EC approval for Uplinza in gMG
• Positive Sentiment: Amgen announced an increase to its dividend to $2.52, which boosts yield and signals management confidence in cash flow — typically supportive for a large-cap, dividend-oriented stock. Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.52
• Positive Sentiment: Unusually large call-option activity (roughly 320,232 calls bought) points to short-term bullish positioning by some investors, which can amplify upside moves in the stock. (No source link provided in feed)
• Neutral Sentiment: Amgen will present at Citi’s 2026 Virtual Oncology Leadership Summit — a standard investor relations event that raises visibility on oncology programs but is not intrinsically catalytic. AMGEN TO PRESENT AT CITI’S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT
• Neutral Sentiment: Analyst notes are mixed: Argus reiterated a Buy with a $400 target while Guggenheim reaffirmed a Hold — this provides conflicting signals but keeps the stock in analysts’ focus. Here’s What Argus Research and Guggenheim Are Saying About Amgen Inc. (AMGN)
• Neutral Sentiment: Industry coverage (CNBC) on pharma’s resetting priorities — pricing, pipelines and patent cliffs — is a sector-level backdrop that could affect sentiment for large-cap drugmakers like Amgen but is not company-specific. Prices, pipelines and patent cliffs: Inside pharma’s big reset
• Neutral Sentiment: Recent entries on short interest in the data feed appear to be reporting zero shares / NaN changes (likely a reporting glitch) and do not signal a meaningful rise in short positioning. (No link provided)

Amgen Trading Up 0.8%

Shares of Amgen stock opened at $369.19 on Friday. The stock has a market cap of $198.80 billion, a P/E ratio of 25.94, a P/E/G ratio of 3.78 and a beta of 0.46. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $385.12. The business’s 50 day moving average is $337.47 and its 200-day moving average is $313.68.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. During the same period last year, the business earned $5.31 earnings per share. The firm’s revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be paid a dividend of $2.52 per share. The ex-dividend date is Friday, February 13th. This represents a $10.08 annualized dividend and a dividend yield of 2.7%. This is a boost from Amgen’s previous quarterly dividend of $2.38. Amgen’s dividend payout ratio (DPR) is presently 66.90%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.